# NAVX-010-Phase I Tolerability and Pharmacokinetic Study in Healthy Male Subjects

> **NCT03655522** · PHASE1 · COMPLETED · sponsor: **Algenis SpA** · enrollment: 30 (actual)

## Conditions studied

- Safety

## Interventions

- **DRUG:** NAVX-010
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03655522
- **Lead sponsor:** Algenis SpA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-14
- **Primary completion:** 2015-09-02
- **Final completion:** 2015-09-02
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03655522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03655522, "NAVX-010-Phase I Tolerability and Pharmacokinetic Study in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03655522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*